ARCT Arcturus Therapeutics Holdings Inc

Price (delayed)

$7.86

Market cap

$223.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.33

Enterprise value

$50.89M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 25

American Realty Capital Trust, Inc. is a real estate investment trust formed to acquire a diversified portfolio of commercial real estate, primarily freestanding single tenant properties net leased to tenants ...

Highlights
Arcturus Therapeutics Holdings's debt has decreased by 17% YoY and by 3.6% QoQ
Arcturus Therapeutics Holdings's gross profit has shrunk by 76% YoY and by 46% QoQ
The revenue has dropped by 76% year-on-year and by 46% since the previous quarter

Key stats

What are the main financial stats of ARCT

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
3.42%
1 week
29.28%
1 month
17.14%
1 year
-59.08%
YTD
28.22%
QTD
16.96%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$29.37M
Gross profit
$29.37M
Operating income
-$102.35M
Net income
-$93.28M
Gross margin
100%
Net margin
-317.6%
Arcturus Therapeutics Holdings's net margin has shrunk by 121% QoQ
Arcturus Therapeutics Holdings's operating margin has shrunk by 115% QoQ
Arcturus Therapeutics Holdings's gross profit has shrunk by 76% YoY and by 46% QoQ
The revenue has dropped by 76% year-on-year and by 46% since the previous quarter

Price vs fundamentals

How does ARCT's price correlate with its fundamentals

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
1.3
P/S
7.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.73
The company's EPS fell by 49% YoY and by 18% QoQ
ARCT's P/B is 46% lower than its 5-year quarterly average of 2.4
ARCT's equity is down by 26% year-on-year and by 10% since the previous quarter
The revenue has dropped by 76% year-on-year and by 46% since the previous quarter
ARCT's price to sales (P/S) is 73% higher than its last 4 quarters average of 4.4 but 55% lower than its 5-year quarterly average of 17.1

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
Arcturus Therapeutics Holdings's ROIC has plunged by 128% YoY and by 38% from the previous quarter
The company's return on sales has shrunk by 121% QoQ
The ROA has shrunk by 105% YoY and by 29% QoQ
The company's return on equity has shrunk by 87% YoY and by 27% QoQ

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total liabilities has decreased by 33% YoY and by 2.9% QoQ
Arcturus Therapeutics Holdings's total assets has decreased by 27% YoY and by 9% QoQ
Arcturus Therapeutics Holdings's debt is 89% lower than its equity
ARCT's equity is down by 26% year-on-year and by 10% since the previous quarter
Arcturus Therapeutics Holdings's debt has decreased by 17% YoY and by 3.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.